408 related articles for article (PubMed ID: 24259466)
1. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
Lim SM; Westover KD; Ficarro SB; Harrison RA; Choi HG; Pacold ME; Carrasco M; Hunter J; Kim ND; Xie T; Sim T; Jänne PA; Meyerson M; Marto JA; Engen JR; Gray NS
Angew Chem Int Ed Engl; 2014 Jan; 53(1):199-204. PubMed ID: 24259466
[TBL] [Abstract][Full Text] [Related]
2. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.
Hunter JC; Gurbani D; Ficarro SB; Carrasco MA; Lim SM; Choi HG; Xie T; Marto JA; Chen Z; Gray NS; Westover KD
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8895-900. PubMed ID: 24889603
[TBL] [Abstract][Full Text] [Related]
3.
Pálfy G; Vida I; Perczel A
Biomol NMR Assign; 2020 Apr; 14(1):1-7. PubMed ID: 31468366
[TBL] [Abstract][Full Text] [Related]
4. Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange.
Nnadi CI; Jenkins ML; Gentile DR; Bateman LA; Zaidman D; Balius TE; Nomura DK; Burke JE; Shokat KM; London N
J Chem Inf Model; 2018 Feb; 58(2):464-471. PubMed ID: 29320178
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of mutant Ras protein through covalent binding.
Rudolph J; Stokoe D
Angew Chem Int Ed Engl; 2014 Apr; 53(15):3777-9. PubMed ID: 24590864
[TBL] [Abstract][Full Text] [Related]
8. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Nonfunctional Ras.
Nussinov R; Jang H; Gursoy A; Keskin O; Gaponenko V
Cell Chem Biol; 2021 Feb; 28(2):121-133. PubMed ID: 33440168
[TBL] [Abstract][Full Text] [Related]
10. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
Goody RS; Müller MP; Rauh D
Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
[TBL] [Abstract][Full Text] [Related]
11. High-frequency 94 GHz ENDOR characterization of the metal binding site in wild-type Ras x GDP and its oncogenic mutant G12V in frozen solution.
Bennati M; Hertel MM; Fritscher J; Prisner TF; Weiden N; Hofweber R; Spörner M; Horn G; Kalbitzer HR
Biochemistry; 2006 Jan; 45(1):42-50. PubMed ID: 16388579
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule modulation of Ras signaling.
Spiegel J; Cromm PM; Zimmermann G; Grossmann TN; Waldmann H
Nat Chem Biol; 2014 Aug; 10(8):613-22. PubMed ID: 24929527
[TBL] [Abstract][Full Text] [Related]
13. Covalent Guanosine Mimetic Inhibitors of G12C KRAS.
Xiong Y; Lu J; Hunter J; Li L; Scott D; Choi HG; Lim SM; Manandhar A; Gondi S; Sim T; Westover KD; Gray NS
ACS Med Chem Lett; 2017 Jan; 8(1):61-66. PubMed ID: 28105276
[TBL] [Abstract][Full Text] [Related]
14. The Ras-Membrane Interface: Isoform-specific Differences in The Catalytic Domain.
Parker JA; Mattos C
Mol Cancer Res; 2015 Apr; 13(4):595-603. PubMed ID: 25566993
[TBL] [Abstract][Full Text] [Related]
15. A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C).
Li N; Liu CF; Zhang W; Rao GW
Curr Med Chem; 2023 Nov; ():. PubMed ID: 37936461
[TBL] [Abstract][Full Text] [Related]
16. DRoP: a water analysis program identifies Ras-GTP-specific pathway of communication between membrane-interacting regions and the active site.
Kearney BM; Johnson CW; Roberts DM; Swartz P; Mattos C
J Mol Biol; 2014 Feb; 426(3):611-29. PubMed ID: 24189050
[TBL] [Abstract][Full Text] [Related]
17. Biochemical And Tumorigenic Effects Of Redox Modification Of Ras-G12c By Nitric Oxide.
Crowe M
Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162270
[TBL] [Abstract][Full Text] [Related]
18. Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors.
Goebel L; Kirschner T; Koska S; Rai A; Janning P; Maffini S; Vatheuer H; Czodrowski P; Goody RS; Müller MP; Rauh D
Elife; 2023 Mar; 12():. PubMed ID: 36972177
[TBL] [Abstract][Full Text] [Related]
19. Covalent Targeting of Ras G12C by Rationally Designed Peptidomimetics.
Yoo DY; Hauser AD; Joy ST; Bar-Sagi D; Arora PS
ACS Chem Biol; 2020 Jun; 15(6):1604-1612. PubMed ID: 32378881
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis.
Prakash P; Zhou Y; Liang H; Hancock JF; Gorfe AA
Biophys J; 2016 Mar; 110(5):1125-38. PubMed ID: 26958889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
